Cullgen will participate in the 44th J.P. Morgan Healthcare Conference held from January 12, 2026, presenting development progress including the planned start of Phase 2 clinical trials for the new non-opioid analgesic CG001419 in Q2 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-01-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/2160-20260108-01.pdf","jir_short_summary":"Cullgen will participate in the 44th J.P. Morgan Healthcare Conference held from January 12, 2026, presenting development progress including the planned start of Phase 2 clinical trials for the new non-opioid analgesic CG001419 in Q2 2026.","jir_summary":"### Cullgen's Conference Participation and Development Progress\nCullgen Inc., a consolidated subsidiary of GNI Corporation, will participate in the 44th J.P. Morgan Healthcare Conference held in San Francisco, USA, starting January 12, 2026. This is one of the world\u2019s largest investor conferences in the healthcare industry, and Cullgen has released its latest corporate presentation materials. These materials indicate that the new non-opioid analgesic candidate CG001419 is scheduled to begin Phase 2 clinical trials in Q2 2026, and that the targeted protein degrader development program for inflammatory diseases has advanced to the IND application preparation stage.\n\n### Impact on Investors and Future Outlook\nCullgen's latest development progress demonstrates strengthening of its pipeline, with upcoming clinical trial initiation expected to drive tangible progress towards commercialization. Participation in the J.P. Morgan Healthcare Conference provides an important platform for information dissemination to global investors and industry stakeholders, enhancing opportunities for fundraising and partnerships. These developments may contribute significantly to the business growth of GNI Corporation, making them noteworthy for investors.","jir_financial_highlights":"New Non-Opioid Analgesic Candidate CG001419: Phase 2 clinical trial planned to start in Q2 2026 (Unknown)\nTargeted Protein Degrader Development Program for Inflammatory Diseases: Advanced to IND application preparation stage (Unknown)","jir_category":"","jir_hashtags":"#GNI, #business_update, #JapaneseStocks","jir_key_figures":"New Non-Opioid Analgesic Candidate CG001419: Phase 2 clinical trial planned to start in Q2 2026\nTargeted Protein Degrader for Inflammatory Diseases: Advanced to IND application preparation stage\nJ.P. Morgan Healthcare Conference Participation Date: From January 12, 2026","jir_meta_title":"GNI Corporation Subsidiary Cullgen Participates in J.P. Morgan Healthcare Conference and Announces New Drug Development Progress","jir_meta_description":"Cullgen, a consolidated subsidiary of GNI Corporation, announces the planned start of Phase 2 clinical trials for the new non-opioid analgesic CG001419 in Q2 2026. Development updates disclosed at the J.P. Morgan Healthcare Conference.","jir_og_title":"Cullgen Announces Participation in J.P. Morgan Healthcare Conference and New Drug Development Progress","jir_og_description":"Cullgen, a subsidiary of GNI Corporation, announces the start of Phase 2 clinical trials for a new drug in Q2 2026. Latest information is shared at the conference.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-15234","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n